A group of researchers have designed a new fuzzy ontology-based system to help people in disagreement reach consensus. This system, which acts as a virtual moderator, is a step forward in the field on Artificial Intelligence. This tool can be useful in making everyday decisions -such as choosing a wine in a restaurant-, but it can also be helpful in complex negotiations between countries fighting for their interests in the European Union framework.

Fuzzy ontologies represent the relationships among basic concepts. This new system uses ontology to help in the decision-making process by acting as a virtual moderator trying to bridge positions among the different parts in a negotiation.
The authors of this study are Ignacio Javier Pérez and Enrique Herrera Viedma, researchers at the SECABA laboratory of the University of Granada, in collaboration with researchers at the Institute for Advanced Management Systems Research (IAMSR) of the Abo Akademi, Finland.
According to the University of Granada professor,Enrique Herrera Viedma, principal investigator of the study, «ontology represents a large amount of information that can be used by a virtual moderator to exert influence on negotiators and help reach consensus.»
Accordingly, the University of Granada research groups on decision-making processes and virtual moderators and the Abo Akademi research groups on ontology and knowledge representation «have joined to design a new tool which is a step forward in the field of decision making and poses new challenges to Applied Artificial Intelligence,» professor Viedma states.

Descargar

A group of researchers have designed a new fuzzy ontology-based system to help people in disagreement reach consensus. This system, which acts as a virtual moderator, is a step forward in the field on Artificial Intelligence. This tool can be useful in making everyday decisions -such as choosing a wine in a restaurant-, but it can also be helpful in complex negotiations between countries fighting for their interests in the European Union framework.

Fuzzy ontologies represent the relationships among basic concepts. This new system uses ontology to help in the decision-making process by acting as a virtual moderator trying to bridge positions among the different parts in a negotiation.
The authors of this study are Ignacio Javier Pérez and Enrique Herrera Viedma, researchers at the SECABA laboratory of the University of Granada, in collaboration with researchers at the Institute for Advanced Management Systems Research (IAMSR) of the Abo Akademi, Finland.
According to the University of Granada professor,Enrique Herrera Viedma, principal investigator of the study, «ontology represents a large amount of information that can be used by a virtual moderator to exert influence on negotiators and help reach consensus.»
Accordingly, the University of Granada research groups on decision-making processes and virtual moderators and the Abo Akademi research groups on ontology and knowledge representation «have joined to design a new tool which is a step forward in the field of decision making and poses new challenges to Applied Artificial Intelligence,» professor Viedma states.

Descargar

Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction.

Transplant rejection
Scientists from the University of Granada have patented a compound made from melatonin that is effective in the treatment and prevention of mucositis, one of the most unpleasant side effects of chemotherapy and radiotherapy in cancer patients. It is an easily applied gel that «is believed to be the first product developed anywhere in the world to combat mucositis,» according to investigators from the Biomedical Research Centre in Granada. There is currently no treatment for this problem because its physiopathology is still not understood.
Mucositis is an inflammatory reaction that affects the mucous membranes throughout the digestive tract from the mouth to the anus, and is one of the principle adverse effects resulting from chemotherapy, radiotherapy and bone marrow transplants. This problem severely complicates the treatment of cancer as patients frequently have to be admitted to hospital, naso-gastric tubes and opiates must be used and, most seriously, radiotherapy treatment against the cancer is interrupted. On some occasions, the results can be fatal.
Radiotherapy and Mucositis
It is estimated that 40% of patients who receive radiotherapy and up to 70% of bone marrow transplant patients will develop mucositis. In patients with cancer of the head and neck, 97% develop this condition to some degree, while 100% of those who receive staged radiotherapy over a prolonged period also suffer from mucositis.
At the moment no effective treatment for mucositis exists, which is why the product developed at the University of Granada is of interest to the medical world and the pharmaceutical industry, given that it could greatly enhance the quality of life of cancer patients.
This patented compound is the fruit of more than twenty years of research into the properties of melatonin at the University of Granada, which has shown that mitochondrial damage is present in cases of mucositis. «Melatonin alleviates the inflammatory reaction and protects the mitochondria,´ says Germaine Escames Rosa, the principal author of the study, «and for this reason we think it could be useful for treating mucositis.»
The success of the treatment developed at the University of Granada is due to the type of gel used in the pharmaceutical formulation, and the amount of melatonin used. «The oral application of this melatonin gel at a specific concentration, impregnates the mucous membranes and reverses the mitochondrial damage, preventing the appearance of mucositis in 100% of cases.» Any other type of melatonin application, such as different concentrations, would not have the s

Descargar

Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction.

Transplant rejection
Scientists from the University of Granada have patented a compound made from melatonin that is effective in the treatment and prevention of mucositis, one of the most unpleasant side effects of chemotherapy and radiotherapy in cancer patients. It is an easily applied gel that «is believed to be the first product developed anywhere in the world to combat mucositis,» according to investigators from the Biomedical Research Centre in Granada. There is currently no treatment for this problem because its physiopathology is still not understood.
Mucositis is an inflammatory reaction that affects the mucous membranes throughout the digestive tract from the mouth to the anus, and is one of the principle adverse effects resulting from chemotherapy, radiotherapy and bone marrow transplants. This problem severely complicates the treatment of cancer as patients frequently have to be admitted to hospital, naso-gastric tubes and opiates must be used and, most seriously, radiotherapy treatment against the cancer is interrupted. On some occasions, the results can be fatal.
Radiotherapy and Mucositis
It is estimated that 40% of patients who receive radiotherapy and up to 70% of bone marrow transplant patients will develop mucositis. In patients with cancer of the head and neck, 97% develop this condition to some degree, while 100% of those who receive staged radiotherapy over a prolonged period also suffer from mucositis.
At the moment no effective treatment for mucositis exists, which is why the product developed at the University of Granada is of interest to the medical world and the pharmaceutical industry, given that it could greatly enhance the quality of life of cancer patients.
This patented compound is the fruit of more than twenty years of research into the properties of melatonin at the University of Granada, which has shown that mitochondrial damage is present in cases of mucositis. «Melatonin alleviates the inflammatory reaction and protects the mitochondria,´ says Germaine Escames Rosa, the principal author of the study, «and for this reason we think it could be useful for treating mucositis.»
The success of the treatment developed at the University of Granada is due to the type of gel used in the pharmaceutical formulation, and the amount of melatonin used. «The oral application of this melatonin gel at a specific concentration, impregnates the mucous membranes and reverses the mitochondrial damage, preventing the appearance of mucositis in 100% of cases.» Any other type of melatonin application, such as different concentrations, would not have the s

Descargar

Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction.

Transplant rejection
Scientists from the University of Granada have patented a compound made from melatonin that is effective in the treatment and prevention of mucositis, one of the most unpleasant side effects of chemotherapy and radiotherapy in cancer patients. It is an easily applied gel that «is believed to be the first product developed anywhere in the world to combat mucositis,» according to investigators from the Biomedical Research Centre in Granada. There is currently no treatment for this problem because its physiopathology is still not understood.
Mucositis is an inflammatory reaction that affects the mucous membranes throughout the digestive tract from the mouth to the anus, and is one of the principle adverse effects resulting from chemotherapy, radiotherapy and bone marrow transplants. This problem severely complicates the treatment of cancer as patients frequently have to be admitted to hospital, naso-gastric tubes and opiates must be used and, most seriously, radiotherapy treatment against the cancer is interrupted. On some occasions, the results can be fatal.
Radiotherapy and Mucositis
It is estimated that 40% of patients who receive radiotherapy and up to 70% of bone marrow transplant patients will develop mucositis. In patients with cancer of the head and neck, 97% develop this condition to some degree, while 100% of those who receive staged radiotherapy over a prolonged period also suffer from mucositis.
At the moment no effective treatment for mucositis exists, which is why the product developed at the University of Granada is of interest to the medical world and the pharmaceutical industry, given that it could greatly enhance the quality of life of cancer patients.
This patented compound is the fruit of more than twenty years of research into the properties of melatonin at the University of Granada, which has shown that mitochondrial damage is present in cases of mucositis. «Melatonin alleviates the inflammatory reaction and protects the mitochondria,´ says Germaine Escames Rosa, the principal author of the study, «and for this reason we think it could be useful for treating mucositis.»
The success of the treatment developed at the University of Granada is due to the type of gel used in the pharmaceutical formulation, and the amount of melatonin used. «The oral application of this melatonin gel at a specific concentration, impregnates the mucous membranes and reverses the mitochondrial damage, preventing the appearance of mucositis in 100% of cases.» Any other type of melatonin application, such as different concentrations, would not have the s

Descargar